Table 2. Characteristics of 1200 PROMMTT patients by clinical site.
| Sites | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |
| Demographics | ||||||||||
| N | 306 | 134 | 61 | 127 | 121 | 109 | 99 | 121 | 94 | 28 |
| Men | 223 | 104 | 42 | 95 | 95 | 80 | 75 | 82 | 68 | 23 |
| Women | 83 | 30 | 19 | 32 | 26 | 29 | 24 | 39 | 26 | 5 |
| Injury | ||||||||||
| Blunt | 213 | 61 | 40 | 98 | 92 | 66 | 50 | 84 | 56 | 17 |
| Penetrating | 93 | 73 | 21 | 29 | 29 | 43 | 49 | 37 | 38 | 11 |
| Unknown | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 5 |
| Death | 68 | 23 | 14 | 22 | 18 | 19 | 23 | 42 | 24 | 5 |
| Death % | 22.2 | 17.2 | 23.3 | 17.2 | 13.5 | 17.3 | 22.1 | 34.7 | 25.0 | 17.9 |
| ISS | ||||||||||
| Score | 25 (16-34) | 25 (16-34) | 29.5 (18.2-42) | 22 (16-34) | 24 (13-35.5) | 17 (10-27) | 22 (16-35) | 34 (22-43) | 22 (10.2-34) | 20.5 (9-35.5) |
| Significant to other sites* | 6,8 | 6,8 | 6 | 6,8 | 8 | 1-4,8 | 8 | 1,2,4-7,9 | 8 | - |
| Fluids | ||||||||||
| IVF given (ml) | 775 (350-1287) | 500 (250-1000) | 450 (200-775) | 500 (375-1000) | 800 (300-1700) | 800 (425-1200) | 250 (100-500) | 1500 (900-2500) | 750 (362-1500) | 1000 (500-1000) |
| Significant to other sites* | 2,7,8 | 1,5,8 | 8 | 7,8 | 2,7,8 | 7,8 | 1,4-6,8-10 | 1-7,9,10 | 7,8 | 7,8 |
*
Significant differences ≥ 0.001